Economic evaluations of assisted reproductive technologies (ART) for specialized infertility treatment: a systematic review of IVF, IUI and ICSI [0.03%]
辅助生殖技术（ART）的经济学评估——系统综述：IVF、IUI和ICSI在特殊不孕症治疗中的应用
Mehdi Khakian,Aghdas Souresrafil,Farahnaz Farzaneh et al.
Mehdi Khakian et al.
Introduction: Couples suffering from infertility range between 10 and 15% worldwide. As assisted reproductive technologies revolutionize treatment, this systematic review synthesizes economic evaluations of these ART meth...
Health impact and cost-effectiveness analysis of introducing a national immunization program with 21-valent versus 20-valent pneumococcal conjugate vaccines for adults ≥65 years of age in Denmark [0.03%]
丹麦老年人群体中引入21价和20价肺炎球菌结合疫苗国家免疫规划的卫生经济效果分析
Oluwaseun Sharomi,Rachel J Oidtman,John C Lang et al.
Oluwaseun Sharomi et al.
Background: Streptococcus pneumoniae is a vaccine-preventable bacterium responsible for invasive pneumococcal disease (IPD). Adults ≥65 are most susceptible to IPD, and pneumococcal vaccines may reduce morbidity and mort...
The economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH [0.03%]
MASH的经济负担：可能患有MASH、未患MASH和确诊MASH患者的医疗资源利用及成本比较
Caichen Zhong,Nana Boame,Semiu O Gbadamosi et al.
Caichen Zhong et al.
Background: This retrospective study compared healthcare resource utilization (HCRU) and costs between patients with probable metabolic dysfunction-associated steatohepatitis (MASH) and those without MASH or those with di...
Comparative landscape of artificial intelligence-assisted systematic literature reviews [0.03%]
人工智能辅助的系统性文献回顾之比较景观分析
Ákos Bernard Józwiak,László Balkányi,Judit Hagymásy
Ákos Bernard Józwiak
Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective [0.03%]
基于INTREPID实际研究数据的单倍吸入三联疗法与多倍吸入三联疗法在慢性阻塞性肺疾病中的经济学分析：从智利公共医疗体系的角度出发
Felipe Moraes Dos Santos,Nicolás Sandoval Astudillo,Manuel Espinoza et al.
Felipe Moraes Dos Santos et al.
Background: Chronic obstructive pulmonary disease (COPD) imposes a substantial economic burden in Chile. This study assessed the cost-effectiveness of fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) once da...
Real-world direct medical costs and resource utilization of immune checkpoint inhibitors in advanced NSCLC with COPD: a multicenter cost-consequence analysis from Iraq [0.03%]
来自伊拉克的多中心成本后果分析：免疫检查点抑制剂在伴有慢性阻塞性肺疾病的晚期非小细胞肺癌患者中的实际直接医疗费用和资源利用状况
Akram Hasan Kareem,Samer Imad Mohammed,Ahmed Abdali Shihad
Akram Hasan Kareem
Background: Immune checkpoint inhibitors (ICIs) are widely used as first-line therapy for advanced non-small cell lung cancer (NSCLC), but their high acquisition cost places substantial pressure on publicly funded healthc...
TENS in chronic pain management: a 11-year nationwide analysis using the French National Health Data System [0.03%]
法国国家健康数据系统中TENS管理慢性疼痛的11年全国范围分析
Vincent Arcani,Anne Donnet,Sylvain Redon
Vincent Arcani
Background: Chronic pain affects one in five people globally, frequently leading to complex polypharmacy. Transcutaneous electrical nerve stimulation (TENS) offers a non-pharmacological alternative to mitigate drug-relate...
Yiola Marcou,Konstantinos Ferentinos,Evros Kitiris et al.
Yiola Marcou et al.
Background: Breast cancer (BC) is the most common cancer among women globally, creating a substantial economic burden on healthcare systems, patients, and society. This study aimed to estimate the annual cost of managing ...
Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-Mutated advanced NSCLC in China [0.03%]
西妥珠单抗治疗中国成人EGFR突变阳性非小细胞肺癌患者的疗效和成本分析
Jing He,Jialin Yu,Ruixuan Liu et al.
Jing He et al.
Background: This study estimated the cost-effectiveness of sacituzumab tirumotecan (Sac-TMT) versus pemetrexed-platinum chemotherapy as second-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in C...
Standardising economic evaluation in Spain's pharmaceutical pricing and reimbursement system: specification, interpretation and integration [0.03%]
西班牙药品价格和报销体系中经济评估的标准化：规定、解释与整合
Marta Trapero-Bertran
Marta Trapero-Bertran
Introduction: Economic evaluation (EE) is a key input for pharmaceutical pricing and reimbursement (P&R), yet countries differ in how EE is specified, interpreted and integrated into decisions. Spain is a timely case: des...